» Articles » PMID: 19906933

Envelope Vaccination Shapes Viral Envelope Evolution Following Simian Immunodeficiency Virus Infection in Rhesus Monkeys

Overview
Journal J Virol
Date 2009 Nov 13
PMID 19906933
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

The evolution of envelope mutations by replicating primate immunodeficiency viruses allows these viruses to escape from the immune pressure mediated by neutralizing antibodies. Vaccine-induced anti-envelope antibody responses may accelerate and/or alter the specificity of the antibodies, thus shaping the evolution of envelope mutations in the replicating virus. To explore this possibility, we studied the neutralizing antibody response and the envelope sequences in rhesus monkeys vaccinated with either gag-pol-nef immunogens or gag-pol-nef immunogens in combination with env and then infected with simian immunodeficiency virus (SIV). Using a pseudovirion neutralization assay, we demonstrate that envelope vaccination primed for an accelerated neutralizing antibody response following virus challenge. To monitor viral envelope evolution in these two cohorts of monkeys, full-length envelopes from plasma virus isolated at weeks 37 and 62 postchallenge were sequenced by single genome amplification to identify sites of envelope mutations. We show that env vaccination was associated with a change in the pattern of envelope mutations. Prevalent mutations in sequences from gag-pol-nef vaccinees included deletions in both variable regions 1 and 4 (V1 and V4), whereas deletions in the env vaccinees occurred only in V1. These data show that env vaccination altered the focus of the antibody-mediated selection pressure on the evolution of envelope following SIV challenge.

Citing Articles

Early preservation of CXCR5+ PD-1+ helper T cells and B cell activation predict the breadth of neutralizing antibody responses in chronic HIV-1 infection.

Cohen K, Altfeld M, Alter G, Stamatatos L J Virol. 2014; 88(22):13310-21.

PMID: 25210168 PMC: 4249103. DOI: 10.1128/JVI.02186-14.


Genetic imprint of vaccination on simian/human immunodeficiency virus type 1 transmitted viral genomes in rhesus macaques.

Varela M, Verschoor E, Lai R, Hughes J, Mooj P, McKinley T PLoS One. 2013; 8(8):e70814.

PMID: 23967111 PMC: 3743870. DOI: 10.1371/journal.pone.0070814.


Envelope variable region 4 is the first target of neutralizing antibodies in early simian immunodeficiency virus mac251 infection of rhesus monkeys.

Yeh W, Brassard L, Miller C, Basavapathruni A, Zhang J, Rao S J Virol. 2012; 86(13):7052-9.

PMID: 22532675 PMC: 3416332. DOI: 10.1128/JVI.00107-12.


Neutralizing antibodies and control of HIV: moves and countermoves.

Hessell A, Haigwood N Curr HIV/AIDS Rep. 2011; 9(1):64-72.

PMID: 22203469 DOI: 10.1007/s11904-011-0105-5.


Immune and Genetic Correlates of Vaccine Protection Against Mucosal Infection by SIV in Monkeys.

Letvin N, Rao S, Montefiori D, Seaman M, Sun Y, Lim S Sci Transl Med. 2011; 3(81):81ra36.

PMID: 21543722 PMC: 3718279. DOI: 10.1126/scitranslmed.3002351.


References
1.
Franchini G, Gurgo C, Guo H, Gallo R, Collalti E, Fargnoli K . Sequence of simian immunodeficiency virus and its relationship to the human immunodeficiency viruses. Nature. 1987; 328(6130):539-43. DOI: 10.1038/328539a0. View

2.
Rong R, Bibollet-Ruche F, Mulenga J, Allen S, Blackwell J, Derdeyn C . Role of V1V2 and other human immunodeficiency virus type 1 envelope domains in resistance to autologous neutralization during clade C infection. J Virol. 2006; 81(3):1350-9. PMC: 1797511. DOI: 10.1128/JVI.01839-06. View

3.
Ourmanov I, Bilska M, Hirsch V, Montefiori D . Recombinant modified vaccinia virus ankara expressing the surface gp120 of simian immunodeficiency virus (SIV) primes for a rapid neutralizing antibody response to SIV infection in macaques. J Virol. 2000; 74(6):2960-5. PMC: 111793. DOI: 10.1128/jvi.74.6.2960-2965.2000. View

4.
Bunnik E, Pisas L, van Nuenen A, Schuitemaker H . Autologous neutralizing humoral immunity and evolution of the viral envelope in the course of subtype B human immunodeficiency virus type 1 infection. J Virol. 2008; 82(16):7932-41. PMC: 2519599. DOI: 10.1128/JVI.00757-08. View

5.
Chakrabarti B, Kong W, Yang Z, Friborg J, Ling X, King S . Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization. J Virol. 2002; 76(11):5357-68. PMC: 137015. DOI: 10.1128/jvi.76.11.5357-5368.2002. View